NANOBIOTIX Reveals Initial Data from Phase 2 Lung Cancer Trial

NANOBIOTIX has unveiled first data from the CONVERGE study at the 2026 European Lung Cancer Conference. The Phase 2 trial, backed by Johnson & Johnson, evaluates the nanoradioenhancer JNJ-1900 (NBTXR3) for stage 3 inoperable non-small cell lung cancer. The study highlighted an acceptable safety profile with no serious treatment-emergent adverse events. Moreover, promising initial efficacy responses were observed, with an objective response rate (ORR) of 71.4% and disease control rate (DCR) of 100% at first disease evaluation, surpassing the estimated benchmark.

JNJ-1900 (NBTXR3), designed as a novel oncology product, showed potential to transform treatment through its unique mechanism activated by radiotherapy. This promising nanotherapeutic approach reflects ongoing collaboration strategies and global co-development efforts with Janssen Pharmaceutica NV.